Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential per Derré, L, Lucca, I, Cesson, V, Bohner, P, Crettenand, F, Rodrigues-Dias, S-C, Dartiguenave, F, Masnada, A, Teixeira-Pereira, C, Benmerzoug, S, Chevalier, MF, Domingos-Pereira, S, Nguyen, S, Polak, L, Schneider, AK, Jichlinski, P, Roth, B, Nardelli-Haefliger, D